PhysIQ and CellCarta think wearables and AI could produce vaccine insights

PhysIQ announced today that it will collaborate with CellCarta to undertake a study using AI in vaccine development.

Enrollment is now complete in the VIII (Vaccine-induced inflammation investigation), which will monitor individual differences in physiologic changes associated with immune system activation in patients receiving vaccinations, including those developed to combat diseases like COVID-19.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0

PhysIQ and CellCarta think wearables and AI could produce vaccine insights

PhysIQ announced today that it will collaborate with CellCarta to undertake a study using AI in vaccine development.

Enrollment is now complete in the VIII (Vaccine-induced inflammation investigation), which will monitor individual differences in physiologic changes associated with immune system activation in patients receiving vaccinations, including those developed to combat diseases like COVID-19.

According to a news release, the study will use blood samples and medical-grade biosensors to continuously monitor and capture remote patient physiology data 24/7, using CellCarta’s capabilities to measure humoral and cellular immune responses with PhysIQ’s proprietary, AI-based analytic program for identifying changes in physiology.

The companies said that such changes in physiology and behavior can be detected within hours after vaccine administration and can be correlated to long-lasting immune responses. The approach aims to identify individu…

Read more
  • 0

How PhysIQ is advancing digital therapeutics through its partnership with Janssen

A partnership with J&J’s Janssen Pharmaceuticals is helping PhysIQ advance with its device-agnostic clinical data collection and analysis platform. 

Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount.

Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence–based technology developer PhysIQ see that the landscape has been reshaped since early 2020.

“Digital medicine has been evolving but a lot of what’s been done has been done in an exploratory capacity,” PhysIQ CCO Chris Economos told MassDevice. “COVID-19 has definitely changed that.”

Get the full story at our sister site, MassDevice.

Read more
  • 0

How PhysIQ is advancing digital therapeutics through its partnership with Janssen

A partnership with J&J’s Janssen Pharmaceuticals is helping PhysIQ advance with its device-agnostic clinical data collection and analysis platform. 

Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount.

Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence–based technology developer PhysIQ see that the landscape has been reshaped since early 2020.

“Digital medicine has been evolving but a lot of what’s been done has been done in an exploratory capacity,” PhysIQ CCO Chris Economos told MassDevice. “COVID-19 has definitely changed that.”

Get the full story at our sister site, MassDevice.

Read more
  • 0

PhysIQ, Janssen partner on digital therapeutics

[Image from PhysIQ]PhysIQ announced today that it is collaborating to license its AccelerateIQTM platform with Janssen Pharmaceuticals.

Chicago-based PhysIQ’s AccelerateIQTM will be licensed to Janssen, a Johnson & Johnson unit so it can deploy it to collect data across its clinical studies through a range of its wearable biosensors, while also utilizing PhysIQ’s portfolio of FDA-cleared digital biomarkers and its medical-grade platform to transform raw data into clinical insight, according to a news release.

The collaboration is set to highlight the maturation of digital medicine and the strategic clinical implications of digital therapeutics for biopharma clinical and commercial teams, the companies say.

PhysIQ noted that a massive push for decentralized trials and a regulatory focus on quality of life markers have propelled biosensor data into a new category as a “must-have” data set to evaluate the safety and efficacy of phar…

Read more
  • 0

PhysIQ hires Scripps Research Translational Institute doctor as chief medical officer

PhysIQ announced today that it appointed the Scripps Research Translational Institute digital medicine director as its chief medical officer.

Dr. Steve Steinhubl will remain with SRTI, where he’s been the director of digital medicine for more than seven years, while he takes on his new role at PhysIQ as he looks to help advance the company’s AI-based analytics platform for improving clinical outcomes and lowering costs, according to a news release.

“Over the last 5 years I’ve been fortunate enough to collaborate with the PhysIQ team on a number of projects,” Steinhubl said in the release. “Their unwavering commitment to evidence-driven research is unparalleled. PhysIQ’s vision and drive for using cutting-edge digital technologies to enable more precise and individualized healthcare makes me extremely proud to be joining their amazing team.

“I look forward to helping expand upon fundamental research into early detection of medical condit…

Read more
  • 0

NIH increases PhysIQ contract to $6.6M

PhysIQ announced today that the National Institutes of Health (NIH) entered into Phase II of a contract for its AI-based COVID-19 biomarker.

A Purdue University-affiliated artificial intelligence company, PhysIQ’s AI-based COVID-19 digital biomarker is being developed to address the rapid decompensation of high-risk COVID-19 patients, according to a news release.

PhysIQ’s technology’s cloud platform continuously collects and processes data from any wearable biosensor. In this case, the platform seeks out biomarkers to determine if a person infected with COVID-19 is experiencing a worsening in their condition.

Instead of using measurements such as temperature and pulse oximetry, PhysIQ’s platform offers multi-parameter vital signs and physiological features which establish a targeted biomarker (COVID-19 Decompensation Index — CDI) for worsening coronavirus-caused condition.

The contract option, exercised by the National Canc…

Read more
  • 0